Erasca, Inc., a clinical-stage precision oncology company founded by University of California chemical biologist Kevan Shokat, today announced promising preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors.
